Abstract
e15567Background: Use of Trastuzumab accrues significant clinical benefit in the HER2 positive metastatic Gastric Cancer (GC) population. However, many patients do not respond to therapy or develop...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
